Tariq Jamal Siddiqi
YOU?
Author Swipe
View article: Coordinated expression of <scp>BMP10</scp>/<scp>ALK1</scp>/endoglin—proteins that drive embryonic cardiac and vascular morphogenesis—in patients with heart failure: The <scp>EMPEROR</scp> Program
Coordinated expression of <span>BMP10</span>/<span>ALK1</span>/endoglin—proteins that drive embryonic cardiac and vascular morphogenesis—in patients with heart failure: The <span>EMPEROR</span> Program Open
Aims Bone morphogenetic protein 10 (BMP10), activin receptor‐like kinase 1 (ALK1) and endoglin form a single transforming growth factor‐β family signalling complex that is the principal driver of cardiac and vascular morphogenesis and matu…
View article: Diuretic Potentiation Strategies in Acute Heart Failure
Diuretic Potentiation Strategies in Acute Heart Failure Open
View article: SGLT2 inhibitors and risk reduction for mortality in high-risk patients: a meta-analysis of randomized controlled trials
SGLT2 inhibitors and risk reduction for mortality in high-risk patients: a meta-analysis of randomized controlled trials Open
Background: The aim of this paper is to assess the impact of sodium-glucose cotransporters-2 (SGLT2) inhibitors on all-cause and cardiovascular (CV) death in high-risk patients and compare the efficacy of empagliflozin and dapagliflozin. M…
View article: SGLT2 inhibitors and risk reduction for mortality in high-risk patients: a meta-analysis of randomized controlled trials
SGLT2 inhibitors and risk reduction for mortality in high-risk patients: a meta-analysis of randomized controlled trials Open
Background: The aim of this paper is to assess the impact of sodium-glucose cotransporters-2 (SGLT2) inhibitors on all-cause and cardiovascular (CV) death in high-risk patients and compare the efficacy of empagliflozin and dapagliflozin. M…
View article: SGLT2 inhibitors and risk reduction for mortality in high-risk patients: a meta-analysis of randomized controlled trials
SGLT2 inhibitors and risk reduction for mortality in high-risk patients: a meta-analysis of randomized controlled trials Open
Background: The aim of this paper is to assess the impact of sodium-glucose cotransporters-2 (SGLT2) inhibitors on all-cause and cardiovascular (CV) death in high-risk patients and compare the efficacy of empagliflozin and dapagliflozin. M…
View article: Clinical Outcomes in Hypertensive Emergency: A Systematic Review and Meta‐Analysis
Clinical Outcomes in Hypertensive Emergency: A Systematic Review and Meta‐Analysis Open
Background To study the prevalence and types of hypertension‐mediated organ damage and the prognosis of patients presenting to the emergency department (ED) with hypertensive emergencies. Methods and Results PubMed was queried from incepti…
View article: Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories Open
The benefit of empagliflozin on major heart failure events was not influenced by KDIGO categories. The magnitude of the renal effects of the drug depended on the approach used to calculate eGFR slopes.
View article: Health status across major subgroups of patients with heart failure and preserved ejection fraction
Health status across major subgroups of patients with heart failure and preserved ejection fraction Open
Aims There are limited data on health status and changes in it over time across major subgroups of patients with heart failure and preserved ejection fraction (HFpEF), including ejection fraction spectrum, age, sex, region, body mass index…
View article: Drugs that slow the progression of diabetic kidney disease: are renoprotective effects attenuated in heart failure?
Drugs that slow the progression of diabetic kidney disease: are renoprotective effects attenuated in heart failure? Open
[Figure: see text]
View article: Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction Open
Background: Women and men with heart failure (HF) and preserved ejection fraction may differ in their clinical characteristics and their response to therapy. The aim of this study was to evaluate the influence of sex on the effects of empa…
View article: Patiromer use in patients with heart failure: lessons and clinical considerations from the DIAMOND trial
Patiromer use in patients with heart failure: lessons and clinical considerations from the DIAMOND trial Open
The benefits of renin–angiotensin–aldosterone system inhibitors (RAASi), including mineralocorticoid receptor antagonists (MRAs), for clinically relevant mortality and morbidity outcomes are strong, consistent across trials and over time, …
View article: Is it safe and effective to administer COVID-19 vaccines during pregnancy? A systematic review and meta-analysis
Is it safe and effective to administer COVID-19 vaccines during pregnancy? A systematic review and meta-analysis Open
View article: Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial Open
Aims To investigate the impact of patiromer on the serum potassium level and its ability to enable specified target doses of renin–angiotensin–aldosterone system inhibitor (RAASi) use in patients with heart failure and reduced ejection fra…
View article: AMSTAR 2 appraisal of systematic reviews and meta-analyses in the field of heart failure from high-impact journals
AMSTAR 2 appraisal of systematic reviews and meta-analyses in the field of heart failure from high-impact journals Open
View article: Outcomes with empagliflozin in heart failure with preserved ejection fraction using <scp>DELIVER</scp>‐like endpoint definitions
Outcomes with empagliflozin in heart failure with preserved ejection fraction using <span>DELIVER</span>‐like endpoint definitions Open
Aims To report data from EMPEROR‐Preserved according to prespecified endpoints of DELIVER. Methods and results In order to assess the impact of DELIVER‐like definition on EMPEROR‐Preserved outcomes, the following differences were reconcile…
View article: Trends in National Institutes of Health R01 Funding of Principal Investigators in Cardiology by Gender
Trends in National Institutes of Health R01 Funding of Principal Investigators in Cardiology by Gender Open
View article: Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials
Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials Open
View article: Early benefit with empagliflozin in heart failure with preserved ejection fraction: <scp>insights from the EMPEROR‐Preserved trial</scp>
Early benefit with empagliflozin in heart failure with preserved ejection fraction: <span>insights from the EMPEROR‐Preserved trial</span> Open
Patients with chronic or worsening heart failure (HF) are at a high risk for morbidity, mortality and impaired health related quality of life (HRQoL). This risk is present in the short-term and increases significantly once hospitalized. Th…
View article: Postmortem findings in COVID-19 fatalities: A systematic review of current evidence
Postmortem findings in COVID-19 fatalities: A systematic review of current evidence Open
View article: Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the <scp>DIAMOND</scp> trial
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the <span>DIAMOND</span> trial Open
Aims In patients with current or a history of hyperkalaemia, treatment with renin–angiotensin–aldosterone system inhibitors (RAASi) is often compromised. Patiromer, a novel potassium (K + ) binder, may improve serum K + levels and adherenc…
View article: AMSTAR 2 Appraisal of Systematic Reviews and Meta-analyses in the Field of Heart Failure from High-impact Journals
AMSTAR 2 Appraisal of Systematic Reviews and Meta-analyses in the Field of Heart Failure from High-impact Journals Open
Background: The MeaSurement Tool to Assess systematic Reviews (AMSTAR) 2 is a critical appraisal tool for systematic reviews (SRs) and meta-analyses (MAs) of interventions. We aimed to perform the first AMSTAR 2-based quality assessment of…
View article: Safety and efficacy of direct oral anticoagulants (DOACs) vs warfarin in patients with concurrent atrial fibrillation and bioprosthetic mitral or aortic valve replacement-a meta analysis
Safety and efficacy of direct oral anticoagulants (DOACs) vs warfarin in patients with concurrent atrial fibrillation and bioprosthetic mitral or aortic valve replacement-a meta analysis Open
Funding Acknowledgements Type of funding sources: None. Background- Bioprosthetic valve (BPV) implantation is preferred over mechanical valves for aortic and mitral valve replacement. BPV can have concurrent atrial fibrillation (AF). Prima…
View article: Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCE‐FMR trial
Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCE‐FMR trial Open
Aims The objective of this study was to compare functional outcomes through 1 year in patients with core‐lab verified moderate to severe (Grades 2+ to 4+) functional mitral regurgitation (FMR) treated with the Carillon device or control in…
View article: Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials
Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials Open
Aims This study aimed to investigate the reporting of subgroup analyses in heart failure (HF) randomized controlled trials (RCTs) and to determine the strength and credibility of subgroup claims. Methods and results All primary HF RCTs pub…
View article: Karachi Cancer Registry (KCR): Age-Standardized Incidence Rate by Age-Group and Gender in a Mega City of Pakistan
Karachi Cancer Registry (KCR): Age-Standardized Incidence Rate by Age-Group and Gender in a Mega City of Pakistan Open
Oral Cancer, a largely preventable cancer is the leading cancer in Karachi adult males while in female adults Breast Cancer is the leading cancer followed by Oral Cancer. In children and adolescents Bone, Leukemia and Brain/CNS malignancie…
View article: Age-Adjusted Risk Factors Associated with Mortality and Mechanical Ventilation Utilization Amongst COVID-19 Hospitalizations—a Systematic Review and Meta-Analysis
Age-Adjusted Risk Factors Associated with Mortality and Mechanical Ventilation Utilization Amongst COVID-19 Hospitalizations—a Systematic Review and Meta-Analysis Open
View article: Is there a smoker’s paradox in COVID-19?
Is there a smoker’s paradox in COVID-19? Open
Although it is well established that cigarette smoking is associated with morbidity and mortality in several respiratory infections, data from recent studies suggest that active smokers are underrepresented among patients with COVID-19. Th…
View article: A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19
A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Open
View article: Ten‐Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs
Ten‐Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs Open
Background In 1993, the US Food and Drug Administration established guidelines to increase diversity by sex and race/ethnicity of participants in clinical trials supporting novel drug approvals. In this study we investigated the 10‐year tr…
View article: Prevalence of Multiplicity and Appropriate Adjustments Among Cardiovascular Randomized Clinical Trials Published in Major Medical Journals
Prevalence of Multiplicity and Appropriate Adjustments Among Cardiovascular Randomized Clinical Trials Published in Major Medical Journals Open
IMPORTANCE: Multiple analyses in a clinical trial can increase the probability of inaccurately concluding that there is a statistically significant treatment effect. However, to date, it is unknown how many randomized clinical trials (RCTs…